IRVINE, CA, and HERSTAL, BELGIUM – June 16, 2016 – MDxHealth SA (Euronext: MDXH.BR), announced today the publication of an editorial in the prestigious journal European Urology that supports the integration of SelectMDx(TM) liquid biopsy test results into established clinical algorithms to improve the detection of high-risk prostate cancer (PCa) [Integrating Molecular Profiling of Liquid Biopsy Samples with a Calculator Algorithm To Detect High-risk Prostate Cancer, Gardiner et al, European Urology (2016)].

“This editorial recognizes SelectMDx as a valuable molecular diagnostic test for the identification of men at risk for aggressive, potentially lethal prostate cancer, improving early detection and opportunity for curative treatment.” stated Dr. Jan Groen, Chief Executive Officer of MDxHealth. “Importantly, the non-invasive, urine-based SelectMDx test can significantly reduce healthcare spending by helping physicians to identify men who can avoid unnecessary invasive and expensive procedures such as prostate biopsies and MRI.”

The editorial addresses the importance of developing an algorithm using established clinical risk factors, combined with a urinary molecular biomarker signature (HOXC6 and DLX1), into a calculator for risk-based patient management. Furthermore, molecular profiling assays, like SelectMDx for Prostate Cancer, provide actionable information about a patient’s risk for aggressive cancer where an mpMRI could aid in the confirmation and localization of potential tumors.

About SelectMDx for Prostate Cancer

Of the nearly 2 million prostate biopsies performed each year, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated complications and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive ‘liquid biopsy’ method to assess a man’s risk for prostate cancer. SelectMDx helps identify men at increased risk of harbouring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce unnecessary MRI procedures and invasive prostate biopsies by approximately 50%, thereby reducing healthcare costs.

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit and follow us on Twitter at:

For more information:


Dr. Jan Groen, CEO
US: +1 949 812 6979
BE: +32 4 364 20 70  




Amber Fennell, Chris Welsh, Hendrik Thys (PR & IR)
Consilium Strategic Communications
UK: +44 20 3709 5701
US: +1 917 322 2571 (Rx Communications Group LLC)



This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.  This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.